Haematological cancer: Optimizing the treatment of multiple myeloma.
Morgan GJ et al. Nat Rev Clin Oncol. 2014 Oct 28. doi: 10.1038/nrclinonc.2014.185. [Epub ahead of print].
The Role of Bendamustine in the Management of Plasma Cell Myeloma.
Gertz MA. Leuk Lymphoma. 2014 Oct 27:1-5. [Epub ahead of print].
Non-hodgkin lymphoma risk and insecticide, fungicide and fumigant use in the agricultural health study.
Alavanja MC et al. PLoS One. 2014 Oct 22;9(10):e109332. doi: 10.1371/journal.pone.0109332. eCollection 2014.
Early discharge after high dose chemotherapy is safe and feasible: a prospective evaluation of 6 years of home care.
Mank AP et al. Leuk Lymphoma. 2014 Oct 20:1-20. [Epub ahead of print].
Allogeneic hematopoietic cell transplantation for concurrent multiple myeloma and myelodysplastic syndrome.
Nishihori T et al. Bone Marrow Transplant. 2014 Oct 20. doi: 10.1038/bmt.2014.233. [Epub ahead of print].
Inequalities in reported cancer patient experience by socio-demographic characteristic and cancer site: evidence from respondents to the English Cancer Patient Experience Survey.
Saunders CL et al. Eur J Cancer Care (Engl). 2014 Oct 18. doi: 10.1111/ecc.12267. [Epub ahead of print].
Human Health Effects of Dichloromethane: Key Findings and Scientific Issues.
Schlosser PM et al. Environ Health Perspect. 2014 Oct 17. [Epub ahead of print].
Fatigue and breathlessness in pregnancy: a rare and sinister cause.
Quigley J et al. BMJ Case Rep. 2014 Oct 16;2014. pii: bcr2014205441. doi: 10.1136/bcr-2014-205441.
Plerixafor: what we still have to learn.
Lanza F et al. Expert Opin Biol Ther. 2014 Oct 15:1-5. [Epub ahead of print].
Thyroid hormones: turning up the heat in myeloma.
Manasanch EE et al. Leuk Lymphoma. 2014 Oct 15:1-5. [Epub ahead of print].
End-of-Life Care for Blood Cancers: A Series of Focus Groups With Hematologic Oncologists.
Odejide OO et al. J Oncol Pract. 2014 Oct 7. pii: JOP.2014.001537. [Epub ahead of print].
Curing myeloma at last: defining criteria and providing the evidence.
Barlogie B et al. Blood. 2014 Oct 7. pii: blood-2014-07-552059. [Epub ahead of print].
Multiple myeloma.
Mehta GR et al. Dis Mon. 2014 Oct 3. pii: S0011-5029(14)00121-7. doi: 10.1016/j.disamonth.2014.08.002. [Epub ahead of print].
What We Mean When We Talk About MRD in Myeloma. A Review of Current Methods. Part 1 of a Two-Part Series.
Ely S et al. Curr Hematol Malig Rep. 2014 Oct 3. [Epub ahead of print].
Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back.
Bianchi G et al. CA Cancer J Clin. 2014 Sep 29. doi: 10.3322/caac.21252. [Epub ahead of print].
Pomalidomide for multiple myeloma.
Fouquet G et al. Expert Rev Hematol. 2014 Sep 30:1-13. [Epub ahead of print].
Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management.
Vincent Rajkumar S. Am J Hematol. 2014 Oct;89(10):999-1009. doi: 10.1002/ajh.23810.
Multiple myeloma.
Anderson KC. Hematol Oncol Clin North Am. 2014 Oct;28(5):xi-xii. doi: 10.1016/j.hoc.2014.08.001.
Immunotherapy strategies in multiple myeloma.
Bae J et al. Hematol Oncol Clin North Am. 2014 Oct;28(5):927-43. doi: 10.1016/j.hoc.2014.07.002.